Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2010
Gabapentin for smoking cessation.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00578552 (Gabapentin for Smoking Abstinence), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gabapentin for Smoking Abstinence
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers.Psychopharmacology · 2012Trial
- Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial.Journal of negative results in biomedicine · 2011Trial
- Consideration of sex and gender differences in addiction medication response.Biology of sex differences · 2022Review
- New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?CNS drugs · 2016Review
- Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.British journal of clinical pharmacology · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
introductionWe conducted a preliminary proof-of-concept study evaluating gabapentin for the treatment of tobacco dependence.
methodsSubjects (N = 80) were randomized to gabapentin (600 mg three times per day or 900 mg three times per day) or placebo. After a 2-week dose titration, the target dose was maintained for 9 weeks and then tapered over 1 week. Follow-up was for 12 weeks after the medication phase.
resultsThe study had high dropout rates with more than one half of participants in each arm discontinuing study. Gabapentin-treated participants exhibited lower abstinence rates than placebo-treated participants; however, this difference was not significant. Smoking reduction was observed across all treatment arms compared with baseline (p < .01) but did not differ across treatment groups. DISCUSSION: Although not definitive, our findings suggest that gabapentin administered at these doses with this dosing regimen holds little promise for the treatment of tobacco dependence in a population of smokers seeking treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.